Table 3 Distribution of women with different quality of life scores in each arm of the EPHT Trial over time
From: Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial
EQ-5D score | |||||
|---|---|---|---|---|---|
Survey year/trial arm | Minimum | 1st quartile | Median | 3rd quartile | Maximum |
2nd year | |||||
Non-blind HT | 0.30 | 0.80 | 0.90 | 1.00 | 1.00 |
Non-treatment | 0.40 | 0.70 | 0.90 | 1.00 | 1.00 |
Blind HT | 0.30 | 0.80 | 0.90 | 1.00 | 1.00 |
Blind placebo | 0.30 | 0.80 | 0.90 | 1.00 | 1.00 |
Final | |||||
Non-blind HT | 0.40 | 0.70 | 0.80 | 0.90 | 1.00 |
Non-treatment | 0.30 | 0.70 | 0.80 | 0.90 | 1.00 |
Blind HT | 0.30 | 0.70 | 0.80 | 0.90 | 1.00 |
Blind placebo | 0.10 | 0.70 | 0.80 | 0.90 | 1.00 |